Chlamydia vaccine shown to be safe in first test in people
Publication date: 17 August 2019Source: New Scientist, Volume 243, Issue 3243Author(s): Jessica Hamzelou
Nature Reviews Urology, Published online: 02 September 2019; doi:10.1038/s41585-019-0232-0First chlamydia vaccine trial in humans
CONCLUSIONS: A tailored practice improvement plan can be envisioned to achieve an optimally functioning STI care continuum. PMID: 31468743 [PubMed - in process]
Three medical stories from the week that we didn't cover, explained.Medscape
All of the women who received the vaccine produced antibodies to chlamydia, but one of the vaccines, called CTH522:CAF01, produced nearly six times more antibodies than the other vaccine, the investigators found.
The first ever chlamydia vaccine to reach the clinical trial stage has passed initial safety tests, reveals a new study published this week.
A potential vaccine for chlamydia, which infects millions each year, has passed an important early test on the road to availability.
A potential vaccine for our most common sexually transmitted infection has passed an important early test on the road to availability.
The first-ever human trial of a genital-chlamydia vaccine suggests that it is safe and effective, according to a new study published in the Lancet. U.S. sexually transmitted illness diagnoses have reached new highs for the past four years in a row, and chlamydia is responsible for the bulk of those infections: 1.7 million cases were diagnosed in 2017 alone, according to the U.S. Centers for Disease Control and Prevention, compared to about 550,000 cases of gonorrhea, 40,000 cases of HIV and 30,000 cases of syphilis. Globally, the problem is even more widespread: about 127 million cases were diagnosed in 2016, according to ...
Scientists from the Statens Serum Institut in Copenhagen tested two injections on 35 healthy female volunteers. After five months, none of the women had suffered any serious side effects.